Monograph
A10AE06 - Insulin Degludec |
Not porphyrinogenic |
NP |
Rationale
Insulin degludec has no porphyrinogenic effects.
Chemical description
Antidiabetic pancreatic hormone consisting of polypeptide chains, connected by disulfide bridges.
Metabolism and pharmacokinetics
Insulin degludec is a basal insulin that forms soluble multi-hexamers upon subcutaneous injection, which are slowly and continuously absorbed into the bloodstream leading to a flat and stable glucose-lowering-effect.
Degradation of insulin degludec is similar to that of human insulin; all metabolites formed are inactive.
Similar drugs
References
# | Citation details | PMID |
---|---|---|
* | Scientific articles | |
1. | Degludec, a new ultra-long-acting basal insulin for the treatment of diabetes mellitus type 1 and 2: advances in clinical research.
Muñoz Torres M. Endocrinol Nutr. 2014 Mar;61(3):153-9. |
23890782 |
* | Summary of Product Characteristics | |
2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Tresiba.
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
© NAPOS 2025